Epidermal growth factor receptor inhibition with erlotinib partially prevents cisplatin-induced nephrotoxicity in rats

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Wada, Yukihiro ^a   Iyoda, Masayuki ^a   Matsumoto, Kei ^a   Shindo Hirai, Yuki ^a   Kuno, Yoshihiro ^a   Yamamoto, Yasutaka ^a   Suzuki, Taihei ^a   Saito, Tomohiro ^a   Iseri, Ken ^a   Shibata, Takanori ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CREATININE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; N ACETYL BETA GLUCOSAMINIDASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HISTOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CORTEX; KIDNEY FUNCTION; KIDNEY MASS; KIDNEY TUBULE CELL; MALE; NEPHROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; RAT; RECEPTOR BLOCKING; RENAL PROTECTION; SIGNAL TRANSDUCTION; UREA NITROGEN BLOOD LEVEL; URINE VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; KIDNEY PROXIMAL TUBULE; LIVER; MACROPHAGE; METABOLISM; PHOSPHORYLATION; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BODY WEIGHT; CELL LINE; CISPLATIN; DRUG-INDUCED LIVER INJURY; HUMANS; KIDNEY TUBULES, PROXIMAL; LIVER; MACROPHAGES; MALE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER;

EID: 84911916469     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111728     Document Type: Article

References (46)

1. Schrier R.W. (2002) Cancer therapy and renal injury. J Clin Invest 110: 743-745.
2. Hanigan MH, Devarajan P (2003) Cisplatin nephrotoxicity. Molecular mechanisms. Cancer Therapy 1: 47-61.
3. de Jonge MJ, Verweij J (2006) Renal toxicities of chemotherapy. Semin Oncol 33: 68-73.
4. Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73: 994-1007.
5. iang M, Wei1 Q, Wang J, Du Q, Yu J, et al. (2006) Regulation of PUMA-a by p53 in cisplatin-induced renal cell apoptosis. Oncogene 25: 4056-4066.
6. Pérol M, Chouaid C, Pérol D, Barlési F, Gervais R, et al. (2012) Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 30: 3516-3524.
7. Singh AB, Harris RC (2005) Autocrine, paracrine and juxtacrine signaling by EGFR ligands. Cell Signal 17: 1183-1193.
8. Tang J, Liu N, Zhuang S (2013) Role of epidermal growth factor receptor in acute and chronic kidney injury. Kidney Int 83: 804-810.
9. Oda K, Matsuoka Y, Funahashi A, Kitano H (2005) A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 1: 1-17.
10. Sorensen OE, Tapa DR, Roupé KM, Valore EV, Sjobring U, et al. (2006) Injury-induced innate immune response in human skin mediated by transactivation of the epidermal growth factor receptor. J Clin Invest 116: 1878-1885.
11. Breyer MD, Redha R, Breyer JA (1990) Segmental distribution of epidermal growth factor binding sites in rabbit nephron. Am J Physiol 259 (4 Pt 2): F553- F558.
12. Coaxum SD, Garnovskaya MN, Gooz M, Baldys A, Raymond JR (2009) Epidermal growth factor activates Na(1/)H(1) exchanger in podocytes through a mechanism that involves Janus kinase and calmodulin. Biochim Biophys Acta 1973: 1174-1181.
13. Nakagawa T, Hayase Y, Sasahara M, Haneda M, Kikkawa R, et al. (1997) Distribution of heparinbinding EGF-like growth factor protein and mRNA in the normal rat kidneys. Kidney Int 51: 1774-1779.
14. Flamant M, Bollee G, Hénique C, Tharaux PL (2012) Epidermal growth factor: a new therapeutic target in glomerular disease. Nephrol Dial Transplant 27: 1297-1304.
15. Chen J, Chen JK, Harris RC (2012) Deletion of the epidermal growth factor receptor in renal proximal tubule epithelial cells delays recovery from acute kidney injury. Kidney Int 82: 45-52.
16. Bollee G, Flamant M, Schordan S, Fligny C, Rumpel E, et al. (2011) Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis. Nat Med 17: 1242-1250.
17. .Ali BH, Al Moundhri MS (2006) Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem Toxicol 44: 1173-1183.
18. Tang J, Liu N, Tolbert E, Ponnusamy M, Ma L, et al. (2013) Sustained activation of EGFR triggers renal fibrogenesis after acute kidney injury. Am J Pathol 183: 160-172.
19. Ali BH Abdelrahman AM Al-Salam S Sudhadevi M AlMahruqi AS et al. 2011 The effect of sildenafil on cisplatin nephrotoxicity in rats Basic Clin Pharmacol Toxicol 109 300-308
20. Iyoda M Shibata T Hirai Y Kuno Y Akizawa T 2011 Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease J Am Soc Nephrol 22 1486-1496
21. Hirai Y, Iyoda M, Shibata T, Kuno Y, Kawaguchi M, et al. (2012) IL-17A stimulates granulocyte colony-stimulating factor production via ERK1/2 but not p38 or JNK in human renal proximal tubular epithelial cells. Am J Physiol Renal Physiol 302: F244-F250.
22. Maeda Y, Fukushima K, Omichi R, Kariya S, Nishizaki K (2013) Time courses of changes in phospho- and total- MAP kinases in the cochlea after intense noise exposure. PLoS One 8: e58775.
23. Hise MK, Salmanullah M, Liu L, Drachenberg CI, Papadimitriou JC, et al. (2001) Control of the epidermal growth factor receptor and its ligands during renal injury. Nephron 88: 71-79.
24. Homma T, Sakai M, Cheng HF, Yasuda T, Coffey RI Jr, et al. (1995) Induction of heparin-binding epidermal growth factor-like growth factor mRNA in rat kidney after acute injury. J Clin Invest 96: 1018-1025.
25. Sakai M, Zhang M, Homma T, Garrick B, Abraham JA, et al. (1997) Production of heparin binding epidermal growth factor-like growth factor in the early phase of regeneration after acute renal injury. Isolation and localization of bioactive molecules. J Clin Invest 99: 2128-2138.
26. Benhar M, Engelberg D, Levitzki A (2002) Cisplatin-induced activation of the EGF receptor. Oncogene 21: 8723-8731.
27. Arany I, Megyesi JK, Kaneto H, Price PM, Safirstein RL (2004) Cisplatininduced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am J Physiol Renal Physiol 287: F543-F549.
28. Kaushal GP, Kaushal V, Hong X, Shah SV (2001) Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. Kidney Int 60: 1726-1736.
29. Cory S, Adams JM (2002) The Bcl2 family: regulators of the cellular life-ordeath switch. Nat Rev Cancer 2: 647-656.
30. Humanes B, Lazaro A, Camano S, Moreno-Gordaliza E, Lazaro JA, et al. (2012) Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats. Kidney Int 82: 652-663.
31. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, et al. (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284.
32. Santarpia L, Lippman SM, El-Naggar AK (2012) Targeting the MAPK-RASRAF signaling pathway in cancer therapy. Expert Opin Ther Targets 16: 103- 119.
33. Wang X, Martindale JL, Holbrook NJ (2000) Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 275: 39435-39443.
34. Jo SK, Cho WY, Sung SA, Kim HK, Won NH (2005) MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis. Kidney Int 67: 458-466.
35. Gao S, Chen T, Choi MY, Liang Y, Xue J, et al. (2013) Cyanidin reverses cisplatin-induced apoptosis in HK-2 proximal tubular cells through inhibition of ROS-mediated DNA damage and modulation of the ERK and AKT pathways. Cancer Lett 333: 36-46.
36. Nowak G (2002) Protein kinase C-alpha and ERK1/2 mediate mitochondrial dysfunction, decreases in active Na+ transport, and cisplatin-induced apoptosis in renal cells. J Biol Chem 277: 43377-43388.
37. Kim YK, Kim HJ, Kwon CH, Kim JH, Woo JS, et al. (2005) Role of ERK activation in cisplatin induced apoptosis in OK renal epithelial cells. J Appl Toxicol 25: 374-382.
38. Kuwana H, Terada Y, Kobayashi T, Okado T, Penninger JM, et al. (2008) The phosphoinositide-3 kinase gamma-Akt pathway mediates renal tubular injury in cisplatin nephrotoxicity. Kidney Int 73: 430-445.
39. Zhuang S, Dang Y, Schnellmann RG (2004) Requirement of the epidermal growth factor receptor in renal epithelial cell proliferation and migration. Am J Physiol Renal Physiol 287: F365-F372.
40. Zhuang S, Duan M, Yan Y (2012) Src family kinases regulate renal epithelial dedifferentiation through activation of EGFR/PI3K signaling. J Cell Physiol 227: 2138-2144
41. He S, Liu N, Bayliss G, Zhuang S (2013) EGFR activity is required for renal tubular cell dedifferentiation and proliferation in a murine model of folic acidinduced acute kidney injury. Am J Physiol Renal Physiol 304: F356-F366.
42. Morigi M, Rota C, Montemurro T, Montelatici E, Lo Cicero V, et al. (2010) Life-sparing effect of human cord blood-mesenchymal stem cells in experimental acute kidney injury. Stem Cells 28: 513-522.
43. Lee JG, Wu R (2012) Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer. PLoS One 7: e48532.
44. Hwang IG, Jang JS, Oh SY, Lee S, Kwon HC, et al. (2012) A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer. Invest New Drugs 30: 2371-2376.
45. Martins RG, Parvathaneni U, Bauman JE, Sharma AK, Raez LE, et al. (2013) Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. J Clin Oncol 31: 1415-1421.
46. Terada Y, Inoue K, Matsumoto T, Ishihara M, Hamada K, et al. (2013) 5- Aminolevulinic acid protects against cisplatin-induced nephrotoxicity without compromising the anticancer efficiency of cisplatin in rats in vitro and in vivo. PLoS One 8: e80850.